The global epigenetics market size is projected to reach USD 4.29 billion by 2030 from USD 2.24 billion in 2025, at a CAGR of 13.9% during the forecast period.
Scope of the Report
Years Considered for the Study
2024-2033
Base Year
2024
Forecast Period
2025-2030
Units Considered
Value (USD billion)
Segments
Offering, Method, Technology, Application, End User (Product), End User (Service), and Region
Regions covered
North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
Factors such as declining sequencing costs and time, along with technological advancements in epigenetics, and a growing demand for epigenetic drugs and diagnostics drive market growth; however, limited applications of epigenomic data in toxicology, along with data privacy and security concerns, restrain market expansion.
"The PCR & qPCR market is likely to grow at a faster pace."
The global epigenetics market is categorized by technology into next-generation sequencing (NGS), polymerase chain reaction (PCR) & quantitative PCR (qPCR), mass spectrometry, sonication, and other methodologies. Notably, the PCR & qPCR segment is projected to exhibit significant compound annual growth rate (CAGR). The rising utilization of methylation-specific PCR techniques enhances the sensitivity and specificity of detecting epigenetic modifications, which is anticipated to drive growth in this segment.
"DNA methylation dominated the method segment."
The epigenetics market is categorized by methodology into several segments, primarily DNA methylation, histone modifications, and other techniques. In 2024, DNA methylation dominated the market, primarily due to its established efficacy in cancer research applications. Furthermore, alternative methodologies-including non-coding RNA analysis and chromatin remodeling-are anticipated to exhibit the highest CAGR throughout the forecast period. This is driven by an increasing focus on innovative epigenetic mechanisms and their prospective roles in diagnostics and therapeutic development.
"Asia Pacific region is estimated to show fastest growth rate."
On the basis of region, the flow cytometry market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, North America accounted for the major share of the epigenetics market. The Asia Pacific region is projected to experience strong growth during the forecast period, fueled by ongoing improvements in healthcare infrastructure across emerging economies. This market is further boosted by strategic collaborations, partnerships, expansions, and agreements initiated by regional industry players.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
By Designation: Managers- 45%, CXOs and Directors- 30%, and Executives- 25%
By Region: North America -35%, Europe - 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%
List of Companies Profiled in the Report:
Thermo Fisher Scientific Inc. (US)
Merck KGaA (Germany)
Illumina, Inc. (US)
PacBio (US)
Danaher (US)
Active Motif, Inc. (US)
Bio-Rad Laboratories Inc. (US)
Promega Corporation (US)
Revvity (US)
Qiagen (Germany)
New England Biolabs (US)
Zymo Research Corporation (US)
Hologic Diagenode (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
EpiGentek Group Inc. (US)
Research Coverage:
This research report categorizes epigenetics market by offering (kits & reagents, enzymes, instruments & accessories, software, and services), method (DNA methylation, Histone modification, and other methods), technology (NGS, PCR & qPCR, mass spectrometry, sonication, and other technologies), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, and other applications), end user for product (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), end user for service (academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report's scope includes detailed information about the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, solutions, and services; key strategies; new product and service launches, acquisitions, and recent developments related to the epigenetics market. This report also covers the competitive analysis of upcoming startups in the epigenetics industry ecosystem.
Key Benefits of Buying the Report:
The report will assist market leaders and new entrants by providing estimates of revenue for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key Drivers (declining sequencing costs & time, expansion of population screening programs, technological advancements in epigenetics research, and rising demand for epigenetic drugs & epigenetics-based diagnostics), restraints (limited applications of epigenomic data in toxicology and data privacy concerns and security issues), opportunities (emerging applications of epigenetics and integration of multi-omics), and challenges (concerns regarding quality of antibodies and challenges associated with epigenetic editing) influencing the growth of the market.
Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the epigenetics market.
Market Development: The report provides comprehensive information about lucrative markets and analyses the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), among others offering products and services for epigenetics market. Other companies include EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), among others, for the epigenetics market.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET SIZE ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET ASSESSMENT
2.3 GROWTH FORECAST MODEL
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIGENETICS MARKET OVERVIEW
4.2 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY